179 related articles for article (PubMed ID: 12649163)
1. SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes.
Giles FJ; Stopeck AT; Silverman LR; Lancet JE; Cooper MA; Hannah AL; Cherrington JM; O'Farrell AM; Yuen HA; Louie SG; Hong W; Cortes JE; Verstovsek S; Albitar M; O'Brien SM; Kantarjian HM; Karp JE
Blood; 2003 Aug; 102(3):795-801. PubMed ID: 12649163
[TBL] [Abstract][Full Text] [Related]
2. Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia.
O'Farrell AM; Yuen HA; Smolich B; Hannah AL; Louie SG; Hong W; Stopeck AT; Silverman LR; Lancet JE; Karp JE; Albitar M; Cherrington JM; Giles FJ
Leuk Res; 2004 Jul; 28(7):679-89. PubMed ID: 15158089
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases.
Giles FJ; Cooper MA; Silverman L; Karp JE; Lancet JE; Zangari M; Shami PJ; Khan KD; Hannah AL; Cherrington JM; Thomas DA; Garcia-Manero G; Albitar M; Kantarjian HM; Stopeck AT
Cancer; 2003 Apr; 97(8):1920-8. PubMed ID: 12673719
[TBL] [Abstract][Full Text] [Related]
4. Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia.
Mesters RM; Padró T; Bieker R; Steins M; Kreuter M; Göner M; Kelsey S; Scigalla P; Fiedler W; Büchner T; Berdel WE
Blood; 2001 Jul; 98(1):241-3. PubMed ID: 11418488
[TBL] [Abstract][Full Text] [Related]
5. Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome.
Roboz GJ; Giles FJ; List AF; Cortes JE; Carlin R; Kowalski M; Bilic S; Masson E; Rosamilia M; Schuster MW; Laurent D; Feldman EJ
Leukemia; 2006 Jun; 20(6):952-7. PubMed ID: 16617323
[TBL] [Abstract][Full Text] [Related]
6. The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts.
Smolich BD; Yuen HA; West KA; Giles FJ; Albitar M; Cherrington JM
Blood; 2001 Mar; 97(5):1413-21. PubMed ID: 11222388
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of VEGF-A, STAT5 and AKT in acute myeloid leukemia blasts of patients treated with SU5416.
Loges S; Tinnefeld H; Metzner A; Jücker M; Butzal M; Bruweleit M; Fischer U; Draab E; Schuch G; O'-Farrel AM; Hossfeld DK; Bokemeyer C; Fiedler W
Leuk Lymphoma; 2006 Dec; 47(12):2601-9. PubMed ID: 17169805
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma.
Zangari M; Anaissie E; Stopeck A; Morimoto A; Tan N; Lancet J; Cooper M; Hannah A; Garcia-Manero G; Faderl S; Kantarjian H; Cherrington J; Albitar M; Giles FJ
Clin Cancer Res; 2004 Jan; 10(1 Pt 1):88-95. PubMed ID: 14734456
[TBL] [Abstract][Full Text] [Related]
9. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia.
Smith BD; Levis M; Beran M; Giles F; Kantarjian H; Berg K; Murphy KM; Dauses T; Allebach J; Small D
Blood; 2004 May; 103(10):3669-76. PubMed ID: 14726387
[TBL] [Abstract][Full Text] [Related]
10. The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Giles FJ; Bellamy WT; Estrov Z; O'Brien SM; Verstovsek S; Ravandi F; Beran M; Bycott P; Pithavala Y; Steinfeldt H; Reich SD; List AF; Yee KW
Leuk Res; 2006 Jul; 30(7):801-11. PubMed ID: 16332390
[TBL] [Abstract][Full Text] [Related]
11. Phase I/II clinical study of topotecan and cytarabine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia and acute myeloid leukemia.
Weihrauch MR; Staib P; Seiberlich B; Hoffmann M; Diehl V; Tesch H
Leuk Lymphoma; 2004 Apr; 45(4):699-704. PubMed ID: 15160942
[TBL] [Abstract][Full Text] [Related]
12. A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia.
Fiedler W; Mesters R; Tinnefeld H; Loges S; Staib P; Duhrsen U; Flasshove M; Ottmann OG; Jung W; Cavalli F; Kuse R; Thomalla J; Serve H; O'Farrell AM; Jacobs M; Brega NM; Scigalla P; Hossfeld DK; Berdel WE
Blood; 2003 Oct; 102(8):2763-7. PubMed ID: 12843001
[TBL] [Abstract][Full Text] [Related]
13. A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study.
Crump M; Hedley D; Kamel-Reid S; Leber B; Wells R; Brandwein J; Buckstein R; Kassis J; Minden M; Matthews J; Robinson S; Turner R; McIntosh L; Eisenhauer E; Seymour L
Leuk Lymphoma; 2010 Feb; 51(2):252-60. PubMed ID: 20109071
[TBL] [Abstract][Full Text] [Related]
14. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.
O'Farrell AM; Abrams TJ; Yuen HA; Ngai TJ; Louie SG; Yee KW; Wong LM; Hong W; Lee LB; Town A; Smolich BD; Manning WC; Murray LJ; Heinrich MC; Cherrington JM
Blood; 2003 May; 101(9):3597-605. PubMed ID: 12531805
[TBL] [Abstract][Full Text] [Related]
15. [Angiogenesis in patients with hematologic malignancies].
Mesters RM; Padró T; Steins M; Bieker R; Retzlaff S; Kessler T; Kienast J; Berdel WE
Onkologie; 2001 Sep; 24 Suppl 5():75-80. PubMed ID: 11600818
[TBL] [Abstract][Full Text] [Related]
16. Aclarubicin and low-dose Cytosine arabinoside in combination with granulocyte colony-stimulating factor in treating acute myeloid leukemia patients with relapsed or refractory disease and myelodysplastic syndrome: a multicenter study of 112 Chinese patients.
Li JM; Shen Y; Wu DP; Liang H; Jin J; Chen FY; Song YP; Song EY; Qiu XF; Hou M; Qiu ZC; Shen ZX
Int J Hematol; 2005 Jul; 82(1):48-54. PubMed ID: 16105759
[TBL] [Abstract][Full Text] [Related]
17. Clinical relevance of vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukaemia and myelodysplastic syndrome.
Verstovsek S; Estey E; Manshouri T; Giles FJ; Cortes J; Beran M; Rogers A; Keating M; Kantarjian H; Albitar M
Br J Haematol; 2002 Jul; 118(1):151-6. PubMed ID: 12100142
[TBL] [Abstract][Full Text] [Related]
18. Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome.
Lee ST; Jang JH; Suh HC; Hahn JS; Ko YW; Min YH
Am J Hematol; 2001 Dec; 68(4):237-45. PubMed ID: 11754412
[TBL] [Abstract][Full Text] [Related]
19. A phase 1/2 study of rigosertib in patients with myelodysplastic syndromes (MDS) and MDS progressed to acute myeloid leukemia.
Navada SC; Fruchtman SM; Odchimar-Reissig R; Demakos EP; Petrone ME; Zbyszewski PS; Holland JF; Silverman LR
Leuk Res; 2018 Jan; 64():10-16. PubMed ID: 29144985
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial.
Zhou X; Mei C; Zhang J; Lu Y; Lan J; Lin S; Zhang Y; Kuang Y; Ren Y; Ma L; Wei J; Ye L; Xu W; Li K; Lu C; Jin J; Tong H
Hematol Oncol; 2020 Oct; 38(4):531-540. PubMed ID: 32469434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
